British drug giant AstraZeneca PLC and Ironwood Pharmaceuticals Inc., a drug development company in Cambridge, are teaming up to develop and then market Ironwood’s new drug for irritable bowel syndrome in China. The drug, called linaclotide, was approved in August by the FDA and is the first in a new class of medicines. The companies will jointly oversee development and marketing in China. The deal calls for Ironwood to receive an upfront payment of $25 million.
Ironwood, AstraZeneca pair up
| Associated Press October 24, 2012
Read it all, now.
Don't miss any of your favorite stories again. Read the stories that matter to you as much as you want, whenever you want when you subscribe to BostonGlobe.com.
Get full access today for just 99¢